(株)ジーエヌアイグループ【2160】の掲示板 2024/03/28〜2024/04/02

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Published: Mar 26, 2024

Data readout from Phase 3 clinical trial in the People's Republic of China (“PRC”) evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025
U.S. Phase 2a clinical trial evaluating F351 for the treatment of NASH-associated liver fibrosis planned for 2025
Appointed Dr. Han Ying as Chief Executive Officer
Acquired indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd. (d/b/a Gyre Pharmaceuticals Co., Ltd) as part of business combination agreement with GNI
Cash and cash equivalents totaled $33.5 million as of December 31, 2023

おいおい中国F351のData readoutが2025年前半？今年中頃完了→今年承認申請→承認じゃなかったのか？

1年遅れかよ。